Pharmacogenetic Assessment of Toxicity After Docetaxel Chemotherapy In Breast Cancer

被引：0
|
作者：
De Lulijs, F. [1 ]
Russo, I. [1 ]
Di Trapani, M. C. [1 ]
Gentile, G. [1 ]
Sgroi, V. [1 ]
Roselli, A. [1 ]
Trasatti, L. [1 ]
Pellegrini, P. [1 ]
Simmaco, M. [1 ]
Marchetti, P. [1 ]
机构：
[1] St Andrea Hosp, Ospd St Andrea, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70925-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S179 / S179
页数：1
相关论文
共 50 条
  • [1] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer
    Hajime Abe
    Tsuyoshi Mori
    Yuki Kawai
    Hirotomi Cho
    Yoshihiro Kubota
    Tomoko Umeda
    Yoshimasa Kurumi
    Tohru Tani
    International Journal of Clinical Oncology, 2013, 18 : 487 - 491
  • [2] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer
    Abe, Hajime
    Mori, Tsuyoshi
    Kawai, Yuki
    Cho, Hirotomi
    Kubota, Yoshihiro
    Umeda, Tomoko
    Kurumi, Yoshimasa
    Tani, Tohru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 487 - 491
  • [3] Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer
    Marsh, Sharon
    Paul, Jim
    King, Cristi R.
    Gifford, Gillian
    McLeod, Howard L.
    Brown, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4528 - 4535
  • [4] Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
    Dong, Ningning
    Yu, Jing
    Wang, Chaoying
    Zheng, Xiaohui
    Wang, Zheng
    Di, Lijun
    Song, Guohong
    Zhu, Budong
    Che, Li
    Jia, Jun
    Jiang, Hanfang
    Zhou, Xinna
    Wang, Xiaoli
    Ren, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (07) : 1197 - 1203
  • [5] Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
    Ningning Dong
    Jing Yu
    Chaoying Wang
    Xiaohui Zheng
    Zheng Wang
    Lijun Di
    Guohong Song
    Budong Zhu
    Li Che
    Jun Jia
    Hanfang Jiang
    Xinna Zhou
    Xiaoli Wang
    Jun Ren
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1197 - 1203
  • [6] Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients
    Sim, Sarah
    Bergh, Jonas
    Hellstroem, Mats
    Hatschek, Thomas
    Xie, Hanjing
    PHARMACOGENOMICS, 2018, 19 (16) : 1259 - 1268
  • [7] Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients
    Cortejoso, Lucia
    Lopez-Fernandez, Luis A.
    PHARMACOGENOMICS, 2012, 13 (10) : 1173 - 1191
  • [8] Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer
    Kaya, A. O.
    Coskun, U.
    Buyukberber, S.
    Benekli, M.
    Tekin, E.
    Cifter, C.
    Ozturk, B.
    Yildiz, R.
    Yaman, E.
    Uner, A.
    Yamac, D.
    JOURNAL OF BUON, 2010, 15 (02): : 248 - 254
  • [9] Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin, and cyclophosphamide as adjuvant chemotherapy for early-stage breast cancer
    Abe, H.
    Umeda, T.
    Kawai, Y.
    Tanaka, M.
    Shimizu, T.
    Chou, H.
    Kubota, Y.
    Mekata, E.
    Kurumi, Y.
    Tani, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Posterior Segment Toxicity after Gemcitabine and Docetaxel Chemotherapy
    Valeshabad, Ali Kord
    Mieler, William F.
    Setlur, Vikram
    Thomas, Merina
    Shahidi, Mahnaz
    OPTOMETRY AND VISION SCIENCE, 2015, 92 (05) : E110 - E113
12345